Original Articles Open access

Evaluation of tramadol/paracetamol 75 mg/650 mg combination therapy for early-stage knee osteoarthritis: a retrospective observational study

Authors

Published
23 July 2025
Section
Original Articles

Abstract

Objective. Knee osteoarthritis (KOA) is a progressive joint disorder that significantly impairs patients’ quality of life. Effective long-term management of KOA remains challenging due to limited pharmacological options and associated adverse effects. This monocentric, retrospective observational study evaluated the efficacy and safety of a fixed-dose tramadol/paracetamol combination (75/650 mg) in alleviating pain in patients with grade I-II KOA according to the Kellgren-Lawrence classification.

Methods. A total of 30 patients treated for 15 days were assessed using the Numerical Rating Scale for pain, the Western Ontario and McMaster Universities Osteoarthritis Index for functional impairment, and the Pittsburgh Sleep Quality Index for sleep quality.

Results. Results showed a 30% and 50% pain reduction in 86% and 43% of patients, respectively, alongside significant improvements in functional mobility and sleep quality. Adverse events, including nausea, itching, and sleepiness, occurred in 10% of patients and did not necessitate treatment discontinuation. Efficacy was consistent across demographic and clinical subgroups, possibly suggesting broad treatment applicability.

Conclusions. While the findings could support tramadol/paracetamol as a safe and effective first-line therapy for KOA, reinforcing its role in optimizing KOA management strategies, limitations such as the small sample size and lack of a control group highlight the need for further research.

Ethics Approval

The study received approval from the Ethical Committee (protocol number C 0.1 RSO ID 2249) and was performed in accordance with the required regulatory specifications, in compliance with the Declaration of Helsinki and the ICH-Good Clinical Practice.

References

  1. Hunter DJ, March L, Chew M. Osteoarthritis in 2020 and beyond: a Lancet Commission. Lancet 2020; 396: 1711-2. DOI: https://doi.org/10.1016/S0140-6736(20)32230-3
  2. Laslett LL, Pelletier JP, Cicuttini FM, Jones G, Martel-Pelletier J. Measuring disease progression in osteoarthritis. Curr Treat Options in Rheum 2016; 2: 97-110. DOI: https://doi.org/10.1007/s40674-016-0041-z
  3. Nilsdotter A, Bremander A. Measures of hip function and symptoms: Harris Hip Score (HHS), Hip Disability and Osteoarthritis Outcome Score (HOOS), Oxford Hip Score (OHS), Lequesne Index of Severity for Osteoarthritis of the Hip (LISOH), and American Academy of Orthopedic Surgeons (AAOS) Hip and Knee Questionnaire. Arthritis Care Res 2011; 63: S200-7. DOI: https://doi.org/10.1002/acr.20549
  4. Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991; 34: 505-14. DOI: https://doi.org/10.1002/art.1780340502
  5. Felson DT, Neogi T, Zhang Y. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med 2000; 133: 635-46 DOI: https://doi.org/10.7326/0003-4819-133-8-200010170-00016
  6. Alshami AM. Knee osteoarthritis related pain: a narrative review of diagnosis and treatment. Int J Health Sci 2014; 8: 85-104. DOI: https://doi.org/10.12816/0006075
  7. Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clin Geriatr Med 2010; 26: 355-69. DOI: https://doi.org/10.1016/j.cger.2010.03.001
  8. Magnusson K, Turkiewicz A, Dell'Isola A, Englund M. Shared genetic factors between osteoarthritis and cardiovascular disease may underlie common etiology. Nat Commun 2024; 15: 9569. DOI: https://doi.org/10.1038/s41467-024-53812-2
  9. Wei G, Lu K, Umar M, Zhu Z, Lu WW, Speakman JR, et al. Risk of metabolic abnormalities in osteoarthritis: a new perspective to understand its pathological mechanisms. Bone Res 2023; 11: 63. DOI: https://doi.org/10.1038/s41413-023-00301-9
  10. Ruscitti P, Di Muzio C, Conforti A, Di Cola I, Pavlych V, Navarini L, et al. Cardiometabolic multimorbidity may identify a more severe subset of rheumatoid arthritis, results from a "real-life" study. Medicine 2023; 102: e33362. DOI: https://doi.org/10.1097/MD.0000000000033362
  11. Hall AJ, Stubbs B, Mamas MA, Myint PK, Smith TO. Association between osteoarthritis and cardiovascular disease: Systematic review and meta-analysis. Eur J Prev Cardiol 2016; 23: 938-46. DOI: https://doi.org/10.1177/2047487315610663
  12. Hu Y, Chen X, Wang S, Jing Y, Su J. Subchondral bone microenvironment in osteoarthritis and pain. Bone Res 2021; 9: 20. DOI: https://doi.org/10.1038/s41413-021-00147-z
  13. Azzini GOM, Santos GS, Visoni SBC, Azzini VOM, Santos RGD, Huber SC, et al. Metabolic syndrome and subchondral bone alterations: the rise of osteoarthritis - a review. J Clin Orthop Trauma 2020; 11: S849-55. DOI: https://doi.org/10.1016/j.jcot.2020.06.021
  14. Chen D, Shen J, Zhao W, Wang T, Han L, Hamilton JL, et al. Osteoarthritis: toward a comprehensive understanding of pathological mechanism. Bone Res 2017; 5: 16044. DOI: https://doi.org/10.1038/boneres.2016.44
  15. Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 2014; 73: 1323-30. DOI: https://doi.org/10.1136/annrheumdis-2013-204763
  16. Li JS, Tsai TY, Clancy MM, Li G, Lewis CL, Felson DT. Weight loss changed gait kinematics in individuals with obesity and knee pain. Gait Posture 2019; 68: 461-5. DOI: https://doi.org/10.1016/j.gaitpost.2018.12.031
  17. Magnusson K, Turkiewicz A, Englund M. Nature vs nurture in knee osteoarthritis - the importance of age, sex and body mass index. Osteoarthritis Cartilage 2019; 27: 586-92. DOI: https://doi.org/10.1016/j.joca.2018.12.018
  18. Gibbs AJ, Gray B, Wallis JA, Taylor NF, Kemp JL, Hunter DJ, et al. Recommendations for the management of hip and knee osteoarthritis: A systematic review of clinical practice guidelines. Osteoarthritis Cartilage 2023; 31: 1280-92. DOI: https://doi.org/10.1016/j.joca.2023.05.015
  19. Lippi L, Ferrillo M, Turco A, Folli A, Moalli S, Refati F, et al. Multidisciplinary rehabilitation after hyaluronic acid injections for elderly with knee, hip, shoulder, and temporomandibular joint osteoarthritis. Medicina 2023; 59: 2047. DOI: https://doi.org/10.3390/medicina59112047
  20. Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 2019; 27: 1578-89. DOI: https://doi.org/10.1016/j.joca.2019.06.011
  21. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012; 64: 465-74. DOI: https://doi.org/10.1002/acr.21596
  22. da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 2017; 390: e21-33. DOI: https://doi.org/10.1016/S0140-6736(17)31744-0
  23. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005; 64: 669-81. DOI: https://doi.org/10.1136/ard.2004.028886
  24. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16: 137-62. DOI: https://doi.org/10.1016/j.joca.2007.12.013
  25. Morón Merchante I, Pergolizzi JV Jr, van de Laar M, Mellinghoff HU, Nalamachu S, O’Brien J, et al. Tramadol/Paracetamol fixed-dose combination for chronic pain management in family practice: a clinical review. ISRN Family Med 2013; 2013: 638469. DOI: https://doi.org/10.5402/2013/638469
  26. Zhu J, Lim A, McCaskie AW, Khanduja V. Viscosupplementation is effective for the treatment of osteoarthritis in the hip: a systematic review. Arthroscopy 2024; 40: 1908-22.e13. DOI: https://doi.org/10.1016/j.arthro.2023.11.010
  27. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014; 22: 363-88. DOI: https://doi.org/10.1016/j.joca.2014.01.003
  28. Pergolizzi JV Jr, van de Laar M, Langford R, Mellinghoff HU, Merchante IM, Nalamachu S, et al. Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain. J Pain Res 2012; 5: 327-46. DOI: https://doi.org/10.2147/JPR.S33112
  29. da Costa BR, Pereira TV, Saadat P, Rudnicki M, Iskander SM, Bodmer NS, et al. Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis. BMJ 2021; 375: n2321. DOI: https://doi.org/10.1136/bmj.n2321
  30. Chen Y, Wang J, Cai J, Zheng T. Efficacy and safety of tramadol/paracetamol combination therapy for moderate to severe pain: a meta-analysis. Medicine 2019; 98: e15226.
  31. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957; 16: 494-502. DOI: https://doi.org/10.1136/ard.16.4.494
  32. Nugent SM, Lovejoy TI, Shull S, Dobscha SK, Morasco BJ. Associations of pain numeric rating scale scores collected during usual care with research administered patient reported pain outcomes. Pain Med 2021; 22: 2235-41. DOI: https://doi.org/10.1093/pm/pnab110
  33. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005; 113: 9-19. DOI: https://doi.org/10.1016/j.pain.2004.09.012
  34. Holtz N, Hamilton DF, Giesinger JM, Jost B, Giesinger K. Minimal important differences for the WOMAC osteoarthritis index and the Forgotten Joint Score-12 in total knee arthroplasty patients. BMC Musculoskelet Disord 2020; 21: 401. DOI: https://doi.org/10.1186/s12891-020-03415-x
  35. McConnell S, Kolopack P, Davis AM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility and measurement properties. Arthritis Rheum 2001; 45: 453-61. DOI: https://doi.org/10.1002/1529-0131(200110)45:5<453::AID-ART365>3.0.CO;2-W
  36. Niu S, Wu Q, Ding S, Wu L, Wang L, Shi Y. Comparison of three measures for insomnia in ischemic stroke patients: Pittsburgh sleep quality index, insomnia severity index, and Athens insomnia scale. Front Neurol 2023; 14: 1118322. DOI: https://doi.org/10.3389/fneur.2023.1118322
  37. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193-213. DOI: https://doi.org/10.1016/0165-1781(89)90047-4
  38. Mullican WS, Lacy JR; TRAMAP-ANAG-006 Study Group. Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: a comparative trial. Clin Ther 2001; 23: 1429-45. DOI: https://doi.org/10.1016/S0149-2918(01)80118-1
  39. Naruge D, Nagashima F, Kawai K, Okano N, Kobayashi T, Furuse J. Tramadol/acetaminophen combination tablets in cancer patients with chemotherapy-induced peripheral neuropathy: a single-arm phase II study. Palliat Med Rep 2020; 1: 25-31. DOI: https://doi.org/10.1089/pmr.2020.0031
  40. Rawal N, Macquaire V, Catalá E, Berti M, Costa R, Wietlisbach M. Tramadol/paracetamol combination tablet for postoperative pain following ambulatory hand surgery: a double-blind, double-dummy, randomized, parallel-group trial. J Pain Res 2011; 4: 103-10. DOI: https://doi.org/10.2147/JPR.S16760
  41. Emkey R, Rosenthal N, Wu SC, Jordan D, Kamin M; CAPSS-114 Study Group. Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. J Rheumatol 2004; 31: 150-6.
  42. Toupin April K, Bisaillon J, Welch V, Maxwell LJ, Jüni P, Rutjes AW, et al. Tramadol for osteoarthritis. Cochrane Database Syst Rev 2019; 5: CD005522. DOI: https://doi.org/10.1002/14651858.CD005522.pub3
  43. Silverfield JC, Kamin M, Wu SC, Rosenthal N; CAPSS-105 Study Group. Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double-blind, placebo-controlled, parallel-group, add-on study. Clin Ther 2002; 24: 282-97. DOI: https://doi.org/10.1016/S0149-2918(02)85024-X
  44. Restuccia R, Ruggieri D, Magaudda L, Talotta R. The preventive and therapeutic role of physical activity in knee osteoarthritis. Reumatismo 2022; 74: 1466. DOI: https://doi.org/10.4081/reumatismo.2022.1466
  45. Park KS, Choi JJ, Kim WU, Min JK, Park SH, Cho CS. The efficacy of tramadol/acetaminophen combination tablets (Ultracet®) as add-on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti-inflammatory drug (NSAID). Clin Rheumatol 2012; 31: 317-23. DOI: https://doi.org/10.1007/s10067-011-1818-y
  46. Kim MS, Koh IJ, Choi KY, Sung YG, Park DC, Lee HJ, et al. The minimal clinically important difference (MCID) for the WOMAC and factors related to achievement of the MCID after medial opening wedge high tibial osteotomy for knee osteoarthritis. Am J Sports Med 2021; 49: 2406-15. DOI: https://doi.org/10.1177/03635465211016853
  47. Angst F, Benz T, Lehmann S, Aeschlimann A, Angst J. Multidimensional minimal clinically important differences in knee osteoarthritis after comprehensive rehabilitation: a prospective evaluation from the Bad Zurzach Osteoarthritis Study. RMD Open 2018; 4: e000685. DOI: https://doi.org/10.1136/rmdopen-2018-000685
  48. Clement ND, Bardgett M, Weir D, Holland J, Gerrand C, Deehan DJ. What is the minimum clinically important difference for the WOMAC index after TKA? Clin Orthop Relat Res 2018; 476: 2005-14. Erratum in: Clin Orthop Relat Res 2020; 478: 922. DOI: https://doi.org/10.1097/CORR.0000000000000444
  49. Sonobe T, Otani K, Sekiguchi M, Otoshi K, Nikaido T, Konno S, et al. Influence of knee osteoarthritis severity, knee pain, and depression on physical function: a cross-sectional study. Clin Interv Aging 2024; 19: 1653-62. DOI: https://doi.org/10.2147/CIA.S470473
  50. Sahbaz T, Cigdem-Karacay B. Assessment of factors affecting quality of life in patients with chronic pain due to knee osteoarthritis and spondylosis: spine versus knee? Reumatismo 2024; 76: 1660. DOI: https://doi.org/10.4081/reumatismo.2024.1660
  51. Buckley JG, Scally AJ, Bhattacharjee C. Living with knee osteoarthritis: the positive impact of reducing the knee torque induced when sleeping supine: a randomized clinical trial. Biomechanics 2022; 2: 95-106. DOI: https://doi.org/10.3390/biomechanics2010010
  52. Parmelee PA, Tighe CA, Dautovich ND. Sleep disturbance in osteoarthritis: linkages with pain, disability, and depressive symptoms. Arthritis Care Res 2015; 67: 358-65. DOI: https://doi.org/10.1002/acr.22459
  53. Sasaki E, Tsuda E, Yamamoto Y, Maeda S, Inoue R, Chiba D, et al. Nocturnal knee pain increases with the severity of knee osteoarthritis, disturbing patient sleep quality. Arthritis Care Res 2014; 66: 1027-32. DOI: https://doi.org/10.1002/acr.22258
  54. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10: 287-333. DOI: https://doi.org/10.1016/j.ejpain.2005.06.009
  55. Zheng S, Tu L, Cicuttini F, Zhu Z, Han W, Antony B, et al. Depression in patients with knee osteoarthritis: risk factors and associations with joint symptoms. BMC Musculoskelet Disord 2021; 22: 40. DOI: https://doi.org/10.1186/s12891-020-03875-1
  56. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004; 43: 879-923. DOI: https://doi.org/10.2165/00003088-200443130-00004
  57. Angeletti C, Guetti C, Paladini A, Varrassi G. Tramadol extended-release for the management of pain due to osteoarthritis. ISRN Pain 2013; 2013: 245346. DOI: https://doi.org/10.1155/2013/245346
  58. Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 2003; 114: 537-45. DOI: https://doi.org/10.1016/S0002-9343(03)00116-5
  59. Anderson BJ. Paracetamol (acetaminophen): mechanisms of action. Paediatr Anaesth 2008; 18: 915-21. DOI: https://doi.org/10.1111/j.1460-9592.2008.02764.x
  60. Im YJ, Jeon JY, Kim EY, Kim Y, Oh DJ, Yoo JS, et al. An assessment of the pharmacokinetics of a sustained-release formulation of a tramadol/acetaminophen combination in healthy subjects. Clin Ther 2015; 37: 376-89. DOI: https://doi.org/10.1016/j.clinthera.2014.12.007
  61. Choi CB, Song JS, Kang YM, Suh CH, Lee J, Choe JY, et al. A 2-week, multicenter, randomized, double-blind, double-dummy, add-on study of the effects of titration on tolerability of tramadol/acetaminophen combination tablet in Korean adults with knee osteoarthritis pain. Clin Ther 2007; 29: 1381-9. DOI: https://doi.org/10.1016/j.clinthera.2007.07.015
  62. Ariani A, Manara M, Fioravanti A, Iannone F, Salaffi F, Ughi N, et al. The Italian Society for Rheumatology clinical practice guidelines for the diagnosis and management of knee, hip and hand osteoarthritis. Reumatismo 2019; 71: 5-21. DOI: https://doi.org/10.4081/reumatismo.2019.1188

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.